Beyond Traditional Screening: The Commercial Potential of Contrast-Enhanced Mammography
Can Contrast-Enhanced Mammography (CEM) bridge the gap between screening and MRI?
Contrast-enhanced mammography (CEM) is emerging as a powerful, cost-effective alternative to Breast MRI for high-risk patients. While MRI remains the gold standard for sensitivity, its high cost and limited availability create access barriers. CEM utilizes existing mammography equipment with the addition of intravenous contrast agents, providing functional vascular information similar to MRI but at a fraction of the cost.
For strategy heads at diagnostic centers, CEM offers a way to diversify their service portfolio without investing millions in a new MRI suite. It allows for more efficient preoperative planning and better assessment of treatment response in oncology patients, making it a high-value tool for integrated breast centers.
How are Breast Cancer Diagnostic Trends shifting toward functional imaging?
Current Breast Cancer Diagnostic Trends indicate a move toward "precision diagnostics." In 2024, clinicians are looking for ways to reduce the "grey area" of inconclusive mammograms. CEM provides the functional data necessary to make definitive decisions, reducing the time from screening to treatment—a key metric for patient outcomes and hospital reputation.
What are the procurement considerations for CEM?
Implementing CEM requires hardware that supports dual-energy acquisition and the integration of contrast injectors. Procurement teams must also consider the additional training required for technicians and the logistics of contrast agent management. In 2025, we expect a rise in "upgrade kits" that allow existing 3D systems to perform CEM.
|
Criteria |
Standard Digital Mammography |
Contrast-Enhanced Mammography (CEM) |
|
Information Type |
Morphological (Anatomy) |
Functional (Vascularity) |
|
Cost per Scan |
Low |
Moderate |
|
Procedure Time |
5-10 minutes |
10-15 minutes |
Strategic Outlook for 2025
In 2025, CEM is projected to become the standard of care for supplemental screening in women with dense breasts who cannot undergo MRI. Diagnostic centers that adopt this early will capture a high-margin patient segment and differentiate themselves in an increasingly competitive imaging market.
Author: Sofiya Sanjay
Designation: Healthcare Research Consultant, Market Research Future
About: At Market Research Future (MRFR), we enable organizations to unravel complex industries through Cooked Research Reports (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact: 99 Hudson Street, 5th Floor, New York, NY 10013, USA | (855) 661-4441 (US) | info@marketresearchfuture.com
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- Games
- Gardening
- Health
- Home
- Literature
- Music
- Networking
- Other
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness